Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 11th February 2019

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the 10th December 2018 Medicines Group meeting were approved and will be circulated.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

- ***Camellia sinensis* (Green Tea) Leaf extract 10% Ointment (Catephen®)**

Requested by GUM. Catephen® is indicated for the cutaneous treatment of external genital and perianal warts (*condylomata acuminata*) in immunocompetent patients from the age of 18 years. It is intended that Catephen® will only be prescribed by GUM as a 2nd line home treatment option for patients where 1st line treatment with Imiquimod and/or Podophyllotoxin has failed or is not indicated/tolerated. Anticipated potential cost to the Trust: £11,115 per annum.
Outcome: Approved for addition to the Formulary

- **Posaconazole 300mg Concentrate for solution for Infusion (Noxafil®)**

Requested by Antimicrobial Stewardship Group. IV Noxafil® is indicated for the treatment of invasive fungal infections in adults. It is intended that Noxafil® IV will only be prescribed on the advice of a microbiologist for patients who are supposed to be on long-term oral posaconazole but unable to take or are intolerant of oral formulations. Suspension formulation of posaconazole has unpredictable absorption and is associated with breakthrough infections. This will avoid the need to switch patients to Ambisome® or Isavuconazole therefore improving continued care and reducing NHS costs. Maximum potential cost to the Trust: £5,064 per annum.
Outcome: Approved for addition to the Formulary

Ex-panel

- **Clonidine 50micrograms/5ml Oral Solution**

New commercially available licensed product available from Thame.
Have been using unlicensed product available from Martindale.
Unlicensed product: £79.52/150ml from Martindale
Licensed product: £66.80p/100mL from Thame.
Outcome: Approved for addition to the Formulary

- **Sunsense Sports Gel SPF50**

Requested by Dermatology for “Day Light PDT”
Topical methyl 5-aminolevulinic acid (MAL) photodynamic therapy (PDT) is effective for the treatment of actinic keratoses. Currently this is applied and managed using conventional PDT. The main limitation of conventional PDT (CPDT) is pain, particularly with large treatment fields.
Daylight PDT (DPDT) solves this problem by reducing the application time of the prodrug MAL to 30 minutes prior to light exposure so that low levels of protoporphyrin IX (PpIX) are generated and continuously photodegraded. It also means more patients can be treated at a time as UV light machines are not required.
Outcome: Approved for addition to the Formulary

- **Triamcinolone Acetonide 40mg/ml Ophthalmic Injection (Intracinol®)**

New commercially available licensed medical device available from Farmigea.
Have been using Triamcinolone Acetonide 40mg/ml (Kenalog®) Unlicensed (Licensed for intra-articular and muscular use).
Kenolog®: £1.66 per vial
Intracinol®: £49.50 per vial

Advantages of Intracinol®:
- Manufactured to ophthalmic grade
- Preservative free (Kenalog® contains Benzyl Alcohol).

Particularly important that an alternative pharmacological treatment option is agreed in light of Ozurdex (Dexamethasone intravitreal implant) recent recall due to presence of silicone particle.
Outcome: Panel requested a full application to be submitted for review at the March TMG

Removals
Nil

NICE Approved drug applications
- **TA545 - Gemtuzumab ozogamicin for untreated acute myeloid leukaemia**

Approved by NICE for untreated AML on 14/11/2018.

Pharmacoeconomic Board requests
- **Pegylated Interferon Alpha for Essential Thrombocythaemia**

Approved by the Pharmacoeconomic Board on 27/12/18
For noting by the Group.
Outcome: Noted

- **Ustekinumab for Psoriatic Enthesitis**

Approved by the Pharmacoeconomic Board on 31/12/2018
For noting by the Group.
Outcome: Noted

IVIG for Pyoderma Gangrenosum (22/11/18)
Approved by the Pharmacoeconomic Board on 22/01/2019
For noting by the Group.
Outcome: Noted

IVIG for Pyoderma Gangrenosum (18/01/19)
Approved by the Pharmacoeconomic Board on 18/01/2019
For noting by the Group.
Outcome: Noted

- **Rituximab for Vasculitis**

Approved by the Pharmacoeconomic Board on 29/01/2019
Outcome: Noted

b) Feedback from NWLIF Meeting - January 2019
Verbal feedback was provided from the NWLIF Meeting held 7th January 2019

4.2 Trust Medicines Policy
Nil

4.3 Medicines Optimisation
- **Compliance to NICE Guidance - MPG2: Patient Group Direction**

Report that summarises the Trust compliance status with NICE Guidance MPG2: Patient Group Direction and

resulting action plan to gain full compliance.

Enclosures include:
- NICE Guidance
- Updated Trust Compliance Status Report (Including Action Plan)
- PGD Audit Plan

The Trust is now fully compliant with this NICE Guidance.
Outcome: Trust compliant to guidance

- **RPSGB: Safe and Secure Handling of Medicines Standards (SSHM)**

Standards launched by RPSGB on 12th December 2018.

Enclosures include:
- Gap Analysis proforma that details all standards
- Project plan

A Gap Analysis is currently being undertaken in all clinical areas and master gap analysis document is being completed. The master Gap Analysis with action plan will be taken back for noting to TMG in due course and noted again at TMG when actions detailed on action plan have been completed.
Outcome: Noted

4.4 NICE Technical Appraisals and Guidance
a) NICE Technical Appraisals

1 Appraisal published in November 2018
7 Appraisals published in December 2018

TA547 - Tofacitinib for moderately to severely active ulcerative colitis
Formulary status / Action
Currently included on the formulary for another indication.
Numbers likely to treat at WMUH Site: 30 year 1 and 60/annum going forward.
Numbers likely to treat at CWH Site: 30 year.

TA548 - Decitabine for untreated acute myeloid leukaemia (Terminated appraisal)
Formulary status / Action
Nil - Terminated appraisal

TA549 - Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)
Formulary status / Action
Nil - Terminated appraisal

TA550 - Vandetanib for treating medullary thyroid cancer
Formulary status / Action
Nil - Not recommended

TA551 - Lenvatinib for untreated advanced hepatocellular carcinoma

Formulary status / Action
Nil action - Not applicable - Condition not treated at CWFT

TA552 - Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Formulary status / Action
Currently included on the formulary.
Numbers likely to treat at CWH site: 1 patient per year.
Numbers likely to treat at WMUH site: 0 patient per year.

TA553 - Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Formulary status / Action
Currently included on the formulary for another indication.
Numbers likely to treat at CWH site: 2 patients per year.
Numbers likely to treat at WMUH site: 0 patients per year.

TA554 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years

Formulary status / Action
Nil action - Not applicable - Condition not treated at CWFT

b) NICE Technology Appraisals published in January 2019

3 Appraisals published in January 2019

TA555 - Regorafenib for previously treated advanced hepatocellular carcinoma
Formulary status / Action
Nil action - Not applicable - Condition not treated at CWFT

TA556 - Darvadstrocel for treating complex perianal fistulas in Crohn's disease
Formulary status / Action
Nil - Not recommended

TA557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Formulary status / Action
Currently included on the formulary for another indication.
Numbers likely to treat at CWH site: 10 patients per year.
Numbers likely to treat at WMUH site: 0 patients per year.

c) NICE Highly Specialised Technologies published since last meeting
0 Highly Specialised Technologies published

4.5 IVIG requests

- **IVIG issues for December 2018 - CW site**

There were 11 IVIG issues in December 2018, with 8 new requests:

- **IVIG issues for December 2018 - WMUH site**

There were 23 IVIG issues in December 2018, with 5 new requests

- **IVIG issues for January 2019 - CWH site**

There were 10 IVIG issues in January 2019, with 7 new requests:

- **IVIG issues for January 2019 - WMUH site**

There were 17 IVIG issues in January 2019, with 7 new requests:

Decision: Approved

4.6 Items for noting

- **Trust Patient Safety Group - Medicines Group & Medicines Safety Group Report - January 2019**

Medicines Group & Medicines Safety Group Report for forwarding to Trust Patient Safety Group for January 2019
Decision: Noted

- **RMOC Checklist for Biosimilar Insulin Lispro**

RMOC Checklist completed for Biosimilar Insulin Lispro which was approved for addition to the Trust Formulary at TMG December 2018 meeting
Decision: Noted

- **Clinical Commissioning Policy - Monthly report - December 2018**

CCP report for December 2018
Decision: Noted

- **Medication Safety Bulletin No 11 re Medicines Waste Guidance**

Medication Safety Bulletin re Medicines Waste Guidance
Decision: Noted

- **Medication Safety Bulletin No.12 re. Medication related incidents**

Medication Safety Bulletin re Medication related incidents
Decision: Noted

- **Faculty of Pain Medicine - Letter re opioid medication**

Letter from Faculty of Pain medicine: Briefing statement to Health Professionals on management of Opioid medications
Decision: Noted

- **MHRA Drug Safety Update - December 2018**

MHRA update for December 2018
Decision: Noted

- **MHRA Drug Safety Update - January 2019**

MHRA update for January 2019
Decision: Noted

4.7 Meeting minutes for noting

- **Medication Safety Group - December 2018**

Minutes from Medication Safety Group - December 2018
Decision: Noted

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - November 2018**

Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting –November 2018
Decision: Noted

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - January 2019**

Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting –December 2018
Decision: Noted

- **Antimicrobial Stewardship Group Meeting - January 2019**

Minutes from Antimicrobial Stewardship Group Meeting - January 2019
Decision: Noted

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

- **Antifungal Stewardship Group Meeting - November 2018**

Minutes from Antimicrobial Stewardship Group Meeting - January 2019
Note: This is a new meeting that has been established under the Antibiotic Stewardship Group.
Decision: Noted

4.8 Additional papers to go to Trust Patient Safety Group
Trust Patient Safety Group - Medicines Group & Medicines Safety Group Report - January 2019

5. Any other business
Nil

6. Date of next meeting
Date: Monday 18th March 2019
Time: 8am-9am
Location: Location: Board Room (CWH Site) and Meeting Room A (WMUH Site) with video conferencing)
Closing date: 22nd February 2019